Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells

At present, 20–30% of children with acute leukemia still relapse from current chemotherapy protocols, underscoring the unmet need for new treatment options, such as proteasome inhibition. Ixazomib (IXA) is an orally available proteasome inhibitor, with an improved safety profile compared to Bortezom...

Descripción completa

Detalles Bibliográficos
Autores principales: Roeten, Margot S.F., van Meerloo, Johan, Kwidama, Zinia J., ter Huizen, Giovanna, Segerink, Wouter H., Zweegman, Sonja, Kaspers, Gertjan J.L., Jansen, Gerrit, Cloos, Jacqueline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8002577/
https://www.ncbi.nlm.nih.gov/pubmed/33802801
http://dx.doi.org/10.3390/cells10030665

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8002577/
https://www.ncbi.nlm.nih.gov/pubmed/33802801
http://dx.doi.org/10.3390/cells10030665

Ejemplares similares